Alector, Inc. (ALEC) News

Alector, Inc. (ALEC): $9.21

0.32 (+3.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALEC to Watchlist
Sign Up

Industry: Biotech


Ranked

of NR

in industry

Filter ALEC News Items

ALEC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ALEC News From Around the Web

Below are the latest news stories about Alector Inc that investors may wish to consider to help them evaluate ALEC as an investment opportunity.

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Source: Company Summary Cyclerion Therapeutics (CYCN) is a spinoff from Ironwood Pharmaceuticals (IRWD) with several clinical failures over the last few years and a strong management team. This distressed situation creates an interesting investment opportunity pending clinical data for the company’s lead asset, CY6463. In 2019, under the pressure of...

Numenor Capital on Seeking Alpha | NA NA, NA

Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online

Source: Company Summary Homology Medicines (FIXX) is a gene therapy and editing platform company centered around hematopoietic stem cells (“HSC”). The investment thesis for Homology builds on top of past analysis on Orchard Therapeutics (ORTX) to use HSCs to potentially cure immune-related disease - Orchard Therapeutics: For Immune-Related Disease (NASDAQ:ORTX)...

Numenor Capital on Seeking Alpha | NA NA, NA


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4524 seconds.